Drug Profile
Extracorporeal hepatocyte-based therapy - Immunic
Alternative Names: ELAD; Extracorporeal bio-artificial liver; VTL C3ALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Vital Therapies
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alcoholic hepatitis; Liver failure
Most Recent Events
- 12 Apr 2019 Immunic merged with Vital Therapies to form Immunic
- 20 Sep 2018 Discontinued - Phase-II/III for Liver failure in Saudi Arabia (Extracorporeal)
- 20 Sep 2018 Discontinued - Phase-III for Alcoholic hepatitis in Ireland, Germany, Spain, United Kingdom, Australia, Australia, USA (Extracorporeal)